Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ)

Immunology Letters

Volumn 142, Issue 1-2, 2012, Pages 34-40

  Odkhuu, Erdenezaya ^a   Koide, Naoki ^a   Haque, Abedul ^a   Tsolmongyn, Bilegtsaikhan ^a   Naiki, Yoshikazu ^a   Hashimoto, Shoji ^a   Komatsu, Takayuki ^a   Yoshida, Tomoaki ^a   Yokochi, Takashi ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

C Fos; Nuclear factor of activated T cells; Osteoclast; Pyrroloquinoline quinine; Receptor activator of nuclear factor B ligand; Type I interferon receptor

Indexed keywords

BETA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON RECEPTOR; INTERFERON RECEPTOR 1; JANUS KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEAR FACTOR OF ACTIVATED T CELL 1; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN C FOS; PYRROLOQUINOLINEQUINONE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; STAT1 PROTEIN; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; CELL STIMULATION; CONTROLLED STUDY; ENZYME ACTIVATION; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; CELL DIFFERENTIATION; CELL LINE; INTERFERON-BETA; MACROPHAGES; MICE; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; PQQ COFACTOR; PROTO-ONCOGENE PROTEINS C-FOS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTOR, INTERFERON ALPHA-BETA; SIGNAL TRANSDUCTION;

EID: 84857189233     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2011.12.001     Document Type: Article

References (37)

1. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
2. Theill L.E., Boyle W.J., Penninger J.M. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 2002, 20:795-823.
3. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007, 7:292-304.
4. Kobayashi N., Kadono Y., Naito A., Matsumoto K., Yamamoto T., Tanaka S., et al. Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. EMBO J 2001, 20:1271-1280.
5. Hotokezaka H., Sakai E., Kanaoka K., Saito K., Matsuo K., Kitaura H., et al. U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells. J Biol Chem 2002, 277:47366-47372.
6. Matsuo K., Galson D.L., Zhao C., Peng L., Laplace C., Wang K.Z., et al. Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem 2004, 279:26475-26480.
7. Nakashima T., Takayanagi H. Osteoimmunology: crosstalk between the immune and bone systems. J Clin Immunol 2009, 29:555-567.
8. Zhao Q., Wang X., Liu Y., He A., Jia R. NFATc1: function in osteoclasts. Int J Biochem Cell Biol 2010, 42:576-579.
9. Grigoriadis A.E., Wang Z.Q., Cecchini M.G., Hofstetter W., Felix R., Fleisch H.A., et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 1994, 266:443-448.
10. Takayanagi H., Kim S., Matsuo K., Suzuki H., Suzuki T., Sato K., et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of IFN-b. Nature 2002, 416:744-749.
11. Takayanagi H., Sato K., Takaoka A., Taniguchi T. Interplay between interferon and other cytokine systems in bone metabolism. Immunol Rev 2005, 208:181-193.
12. Gallop P.M., Paz M.A., Flückiger R., Henson E. Is the antioxidant, anti-inflammatory putative new vitamin, PQQ, involved with nitric oxide in bone metabolism. Connect Tissue Res 1993, 29:153-161.
13. Rucker R., Chowanadisai W., Nakano M. Potential physiological importance of pyrroloquinoline quinone. Altern Med Rev 2009, 14:268-277.
14. Kumazawa T., Seno H., Urakami T., Matsumoto T., Suzuki O. Trace levels of pyrroloquinoline quinone in human and rat samples detected by gas chromatography/mass spectrometry. Biochim Biophys Acta 1992, 1156:62-66.
15. Mitchell A.E., Jones A.D., Mercer R.S., Rucker R.B. Characterization of pyrroloquinoline quinone amino acid derivatives by electrospray ionization mass spectrometry and detection in human milk. Anal Biochem 1999, 269:317-325.
16. Steinberg F.M., Gershwin M.E., Rucker R.B. Dietary pyrroloquinoline quinone: growth and immuno response in BALB/c mice. J Nutr 1994, 124:744-753.
17. Steinberg F., Stites T.E., Anderson P., Storms D., Chan I., Eghbali S., et al. Pyrroloquinoline quinone improves growth and reproductive performance in mice fed chemically defined diets. Exp Biol Med 2003, 228:160-166.
18. Kumazawa T., Hiwasa T., Takiguchi M., Suzuki O., Sato K. Activation of Ras signalling pathways by pyrroloquinoline quinone in NIH3T3 mouse fibroblasts. Int J Mol Med 2007, 19:765-770.
19. Chowanadisai W., Bauerly K.A., Tchaparian E., Wong A., Cortopassi G.A., Rucker R.B. Pyrroloquinoline quinone stimulates mitochondrial biogenesis through cAMP response element-binding protein phosphorylation and increased PGC-1α expression. J Biol Chem 2010, 285:142-152.
20. Caroline M., Hardikar B.P. A method for photomicrography of cytotoxicity in 96-well plates. Asian J Biotechnol 2010, 2:232-238.
21. Islam S., Hassan F., Tumurkhuu G., Dagvadorj J., Koide N., Naiki Y., et al. Bacterial lipopolysaccharide induces osteoclast formation in RAW 264.7 macrophage cells. Biochem Biophys Res Commun 2007, 360:346-351.
22. Kasugai C., Morikawa A., Naiki Y., Koide N., Komatsu T., Yoshida T., et al. Concanavalin A induces formation of osteoclast-like cells in RAW 264.7 mouse macrophage cells. Immunopharmacol Immunotoxicol 2009, 31:103-107.
23. Noman A.S., Koide N., Iftakhar-E-Khuda I., Dagvadorj J., Tumurkhuu G., Naiki Y., et al. Retinoblastoma protein-interacting zinc finger 1 (RIZ1) participates in RANKL-induced osteoclast formation via regulation of NFATc1 expression. Immunol Lett 2010, 131:166-169.
24. Koide N., Naiki Y., Morikawa A., Tumurkhuu G., Dagvadorj J., Noman A.S., et al. Nystatin-induced nitric oxide production in mouse macrophage-like cell line RAW264.7. Microbiol Immunol 2009, 53:295-300.
25. Hsu H., Lacey D.L., Dunstan C.R., Solovyev I., Colombero A., Timms E., et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999, 96:3540-3545.
26. Lean J.M., Matsuo K., Fox S.W., Fuller K., Gibson F.M., Draycott G., et al. Osteoclast lineage commitment of bone marrow precursors through expression of membrane-bound TRANCE. Bone 2000, 27:29-40.
27. Sakai S., Takaishi H., Matsuzaki K., Kaneko H., Furukawa M., Miyauchi Y., et al. 1-Alpha, 25-dihydroxy vitamin D3 inhibits osteoclastogenesis through IFN-beta-dependent NFATc1 suppression. J Bone Miner Metab 2009, 27:643-652.
28. Takayanagi H., Kim S., Koga T., Nishina H., Isshiki M., Yoshida H., et al. Induction and activation of the transcription factor NFATc1 (NFAT2) Integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002, 3:889-901.
29. Ikeda F., Nishimura R., Matsubara T., Tanaka S., Inoue J., Reddy S.V., et al. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J Clin Invest 2004, 114:475-484.
30. Wagner E.F., Eferl R. Fos/AP-1 proteins in bone and the immune system. Immunol Rev 2005, 208:126-140.
31. Matsumoto M., Sudo T., Saito T., Osada H., Tsujimoto M. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J Biol Chem 2000, 275:31155-31161.
32. Abraham A.K., Ramanathan M., Weinstock-Guttman B., Mager D.E. Mechanisms of interferon-beta effects on bone homeostasis. Biochem Pharmacol 2009, 77:1757-1762.
33. Tchaparian E., Marshal L., Cutler G., Bauerly K., Chowanadisai W., Satre M., et al. Identification of transcriptional networks responding to pyrroloquinoline quinone dietary supplementation and their influence on thioredoxin expression, and the JAK/STAT and MAPK pathways. Biochem J 2010, 429:515-526.
34. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998, 95:3597-3602.
35. Fox S.W., Chambers T.J. Interferon-gamma directly inhibits TRANCE-induced osteoclastogenesis. Biochem Biophys Res Commun 2000, 276:868-872.
36. Hume D.A., Loutit J.F., Gordon S. The mononuclear phagocyte system of the mouse defined by immunohistochemical localization of antigen F4/80: macrophages of bone and associated connective tissue. J Cell Sci 1984, 66:189-194.
37. Aizenman E., Jensen F.E., Gallop P.M., Rosenberg P.A., Tang L.H. Further evidence that pyrroloquinoline quinone interacts with the N-methyl-d-aspartate receptor redox site in rat cortical neurons in vitro. Neurosci Lett 1994, 168:189-192.